Business Wire

Ricardo Innovative Climate-Repairing Carbon Negative Technology to Support National Energy Security

Share

As part of its mission to support the decarbonisation of the global energy sector, Ricardo, a world-class, strategic environmental and engineering consulting company, has received 3million GBP from the UK Government to design, install and operate a combined heat and power demonstrator plant with a carbon negative footprint which will showcase climate repairing technology. The plant will demonstrate the effectiveness of community scale greenhouse gas removal and clean energy using sustainably-sourced forestry waste. The funding is awarded through the Net Zero Innovation Portfolio (NZIP) under the Department of Business, Energy and Industrial Strategy (BEIS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005348/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Homested Farm carbon capture demonstrator site (Photo: Business Wire)

Ricardo is leading the consortium delivering the demonstrator plant. The consortium combines an innovative carbon capture system developed by Ricardo with the hot air turbine technology from Bluebox Energy and pyrolysis technology from Woodtek Engineering. The quarter-sized demonstrator plant, which will be located at Holmsted Farm in West Sussex in the UK, will be commissioned and operational in 2023. It will demonstrate not only a highly innovative greenhouse gas removal technology, that in the full-size system can generate renewable heat and electricity for up to 300 local homes and businesses, but also a realistic carbon negative technology that can significantly contribute to net zero targets.

Tim Curtis, Managing Director, Ricardo Energy and Environment said: “Ricardo is a trusted advisor to governments around the world on climate change policy and the transition to clean energy, and is also well known for its mission to decarbonise the global transport and energy sectors. In partnership with Bluebox Energy and Woodtek Engineering, this project will demonstrate that our innovative and integrated carbon capture system can be used to benefit local communities, bolster the UK’s reputation as a pioneer in negative emission technologies, and provide a sustainable and commercially viable pathway to net-zero while also delivering national energy security.”

Ricardo’s project is one of several across the UK which will benefit from a share of over 54 million GBP to develop technologies that remove carbon emissions from the atmosphere. Announcing this investment, UK Government’s Energy and Climate Change Minister Greg Hands said: “This 54 million GBP government investment will help establish a greenhouse gas removal industry in the UK, which could be worth billions to our economy, bringing in private investment and supporting the creation of new green jobs.”

The technology works by taking sustainably sourced waste wood from domestic timber production and then processing it in three ways: producing biochar (a product similar to charcoal); generating heat and power; and capturing carbon dioxide from the exhaust. The technology, therefore, captures around 95% of the carbon content in the wood. It also produces commercially marketable carbon products: the biochar can be used by farmers to enrich soil and add to animal feed to reduce ruminant emissions. The industrial-grade carbon dioxide can either be used for making low-carbon concrete or in the food and drinks industry to replace carbon dioxide derived from industrial processes which rely on imported natural gas. A full-size system will remove 16,000 tonnes of carbon dioxide per year from the atmosphere.

Ricardo has been collaborating with Bluebox Energy since June 2020 to deliver innovative technologies that support the transition to a low carbon future. This project is a further boost to Ricardo’s credentials in tackling climate change and meeting national net zero targets. Ricardo is currently actively supporting clients in Europe in innovative carbon capture technologies and has advised the UK Government on the potential of bioenergy with carbon capture in the UK. Ricardo supports clients across a wide range of industries develop their industrial decarbonisation plans on the route to net zero.

Ends

About Ricardo

Ricardo plc is a world-class strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com

Department for Business, Energy & Industrial Strategy

This funding has been made available from the government’s £1 billion Net Zero Innovation Portfolio, which looks to accelerate the commercialisation of low-carbon technologies and systems, through its Direct Air Capture and Greenhouse Gas Removal Innovation Competition. This competition will provide funding for developing technologies that enable the removal of greenhouse gases from the atmosphere in the UK.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye